Core Viewpoint - Hainan Haiyao indicated that changes in shareholder structure may be influenced by various factors, including market conditions and investor expectations [2] Group 1 - The company responded to investor inquiries on its interactive platform [2] - The potential factors affecting shareholder structure include but are not limited to market environment and investor sentiment [2]

Core Viewpoint - The announcement details the daily related transactions between Hainan Haiyao Co., Ltd. and its affiliate Chongqing Jinsai Pharmaceutical Co., Ltd., with expected transaction amounts for 2026 not exceeding 16 million yuan, following a cash-before-delivery model [1][3]. Group 1: Daily Related Transactions Overview - Hainan Haiyao's board approved the related transactions on December 30, 2025, with revenue from these transactions amounting to 2.81 million yuan in 2025 [1]. - The expected transaction amount for 2026 is capped at 16 million yuan, with payments made in full before delivery [1][3]. Group 2: Affiliate Information - Chongqing Jinsai Pharmaceutical Co., Ltd. is identified as an affiliate, previously holding over 5% of shares in Hainan Haiyao, and is influenced by Liu Xicheng, the actual controller of Shenzhen Nanfang Tongzheng Investment Co., Ltd. [2][3]. Group 3: Transaction Terms and Conditions - The transactions are based on normal commercial practices, adhering to principles of equality, mutual benefit, and fairness, with prices determined through market references [3][7]. - Payment arrangements and settlement methods are executed according to contractual agreements [5][6]. Group 4: Impact on the Company - The related transactions are deemed normal business activities that do not harm the interests of the company or its shareholders, particularly minority shareholders [7][8]. - The company maintains independence from the affiliate in various aspects, ensuring no adverse effects on its financial status or operational results [7][8]. Group 5: Independent Directors' Opinions - Independent directors have reviewed and approved the related transactions, affirming their alignment with the company's business needs and compliance with legal regulations [8].

Group 1 - The core point of the article is that Hainan Haiyao (000566) announced the approval of a proposal regarding daily related transactions during the 30th meeting of its 11th Board of Directors [1] Group 2 - The announcement indicates the company's ongoing engagement in related transactions, which may impact its operational strategy and financial performance [1] - The decision reflects the company's governance practices and adherence to regulatory requirements concerning related party transactions [1] - This move could signal potential opportunities for collaboration or synergies within the company's operational framework [1]

证券代码：000566 证券简称：海南海药 公告编号：2026-002 海南海药股份有限公司 关于日常关联交易的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、 日常关联交易基本情况 海南海药股份有限公司（以下简称"公司"或"海南海药"）于 2025 年 12 月 30 日召开的第十一届董事会第三十次会议审议通过了《关于日常关联交易的 议案》，根据日常经营情况和实际业务开展的需要，公司及控股子公司与关联方 重庆金赛医药有限公司(以下简称"重庆金赛")发生关联交易，2025 年度形成 收入 281 万元，预计 2026 年度日常关联交易金额不超过 1600 万元，上述关联 交易均采用先款后货形式，由重庆金赛先行全款给付给公司，公司再向其发货。 公司董事会审议上述议案时，关联董事刘畅先生、文敏先生已回避表决。董 事会审议前，该议案已经独立董事专门会议审议通过。根据《深圳证券交易所股 票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等法律法规及公司章程的相关规定，上述日常关联交易事项无需提交 股东会审议。 二、关联人介绍 ...

第十一届董事会第三十次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）第十一届董事会第三十次会议 于 2025 年 12 月 30 日以通讯表决方式召开。本次会议于 2025 年 12 月 26 日以电 子邮件等方式送达了会议通知及文件。会议应到董事 9 人，实到董事 9 人，会议 的召开符合《公司法》和《公司章程》有关规定。经与会董事认真审议，表决通 过了如下议案： 公司独立董事已召开专门会议审议本议案，过半数独立董事同意将本议案提 交董事会审议，具体内容详见同日刊载于巨潮资讯网（http://www.cninfo.com.cn） 的《关于日常关联交易的公告》。 表决结果：7 票同意，0 票反对，0 票弃权 特此公告 证券代码：000566 证券简称：海南海药 公告编号：2026-001 海南海药股份有限公司 海南海药股份有限公司 审议《关于日常关联交易的议案》 根据《深圳证券交易所股票上市规则》相关规定，本次交易构成关联交易， 刘畅先生、文敏先生系关联董事，已回避本议案的表决。 董 事 会 二〇二六年一月 ...

Core Viewpoint - Hainan Haiyao's stock price has shown significant volatility, with a year-to-date increase of 51.15%, but a recent decline of 12.56% over the past five trading days [1] Group 1: Stock Performance - As of December 31, Hainan Haiyao's stock price was 7.24 CNY per share, with a trading volume of 5.97 billion CNY and a turnover rate of 6.45%, resulting in a total market capitalization of 93.93 billion CNY [1] - The stock has experienced a 12.56% decline over the last five trading days and a 10.95% decline over the last 20 days, while it has increased by 31.64% over the last 60 days [1] - The company has appeared on the trading leaderboard 10 times this year, with the most recent appearance on December 23, where it recorded a net buy of 241 million CNY [1] Group 2: Company Overview - Hainan Haiyao, established on December 30, 1992, and listed on May 25, 1994, is located in Haikou, Hainan Province, and its main business includes traditional and Western medicine, fine chemicals, chemical raw materials, health products, and related import-export trade [2] - The company's revenue composition includes: Other varieties 29.93%, Gastrointestinal health 25.07%, Medical services 18.60%, Raw materials and intermediates 13.27%, Cephalosporin series 10.19%, and Others 2.95% [2] - Hainan Haiyao is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations, with concepts including anticancer drugs, innovative drugs, antiviral drugs, traditional Chinese medicine, and raw materials [2] Group 3: Financial Performance - For the period from January to September 2025, Hainan Haiyao reported revenue of 640 million CNY, a year-on-year decrease of 20.51%, and a net profit attributable to shareholders of -242 million CNY, reflecting a year-on-year increase of 17.91% [2] - The company has distributed a total of 466 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which held 6.6464 million shares, a decrease of 1.1481 million shares from the previous period [3]

2025年第六次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、特别提示： 1、本次股东会无否决议案的情形； 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000566 证券简称：海南海药 公告编号：2025-082 海南海药股份有限公司 2、本次股东会不涉及变更前次股东会决议的情形。 二、会议召开的情况 1、会议召开的日期、时间： （1）现场会议时间：2025年12月26日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2025年12月26日9:15-9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年12月26日9:15 至15:00的任意时间。 2、召开地点：海南省海口市秀英区南海大道192号海药工业园公司会议室 3、召开方式：现场表决与网络投票相结合。 4、召集人：公司第十一届董事会 5、现场会议主持人：公司第十一届董事会董事长王建平 6、公司部分董事和高级管理人员现场或通过视频方式出席了本次股东会，北京大成(海口)律师事 ...

Mergers and Acquisitions - Huasoft Technology plans to acquire 67% stake in Shandong Lain Optoelectronics, which focuses on the R&D, production, and sales of safety light curtains and related products [1] - TCL Technology's subsidiary TCL Huaxing successfully acquired 80% stake in Fujian Zhaoyuan Optoelectronics and related debts for a total price of 490 million yuan [2] Shareholding Changes - XCMG Machinery's controlling shareholder plans to increase its stake in the company by no less than 80 million yuan and no more than 160 million yuan within six months starting from December 26, 2025 [3] - Chipone Technology's shareholder, the National Integrated Circuit Industry Investment Fund, plans to reduce its stake by up to 1.7%, amounting to a maximum of 893.96 million shares [4] - Huachen Equipment's actual controllers plan to reduce their stake by up to 2%, totaling a maximum of 507.08 million shares within three months after the announcement [5] Investment Agreements - Jinjiang Shipping plans to invest no more than 1.94 billion yuan to build 4+4 container ships with a capacity of 1800 TEU [6] - Zhiguang Electric's subsidiary signed a sales contract worth 119 million yuan for high-voltage cascade energy storage systems [7] - Chalco International signed a project contract worth approximately 14 billion yuan with an overseas client, with no related party relationships involved [8] Regulatory Issues - Pairui Co. is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, with issues related to revenue recognition in a sales contract [9] - *ST Chang Pharmaceutical is facing a potential major illegal delisting due to false financial reporting from 2021 to 2023, which inflated revenue and profit figures [10]

证券日报网讯 12月26日，海南海药发布公告称，公司2025年12月26日召开2025年第六次临时股东会， 审议通过《关于修订并更名为的议案》等。 （文章来源：证券日报） ...

Group 1 - Hainan Airlines (600221) focuses on international, domestic, and regional air passenger and cargo transportation, operating nearly 1800 routes and covering all provinces in China, as well as over 100 international routes [1][30] - Hainan Airport (600515) operates major airports in Hainan and is involved in airport construction, management, and related industries, including aircraft maintenance and logistics [2][31] - Zhongtung High-tech (000657) is a state-owned enterprise focusing on the tungsten and hard alloy industry, with a complete industrial chain from tungsten ore to products, and is involved in high-end manufacturing sectors [3][32] Group 2 - Jinpan Technology (688676) is a key player in the new energy sector, specializing in the research and manufacturing of power distribution and control equipment, benefiting from supportive policies in Hainan [4][33] - Haixia Co., Ltd. (002320) controls important maritime transport routes, enhancing its passenger and cargo transport services, and is positioned to benefit from increased demand post-border closure [5][34] - Hainan Mining (601969) focuses on mineral resource extraction and processing, with products supporting the new energy battery industry, and is exploring green development models [6][35] Group 3 - Hainan Rubber (601118) is a leading enterprise in natural rubber production, extending its business into rubber products and international trade, leveraging Hainan's free trade policies [7][36] - Guangsheng Nonferrous (600259) specializes in non-ferrous metal mining and smelting, with a focus on rare earths and tungsten, essential for high-end manufacturing and new energy sectors [8][37] - Haima Automobile (000572) is transitioning into the new energy vehicle sector, supported by Hainan's policies, and is expanding its production capabilities [9][38] Group 4 - Haide Co., Ltd. (000567) focuses on distressed asset management, with a strategy to optimize asset allocation in the region, and is involved in photovoltaic projects [10][39] - Hainan Public Transport Group (603069) provides passenger transport services and is enhancing its operations through the integration of duty-free services [11][40] - Junda Co., Ltd. (002865) is engaged in the new energy sector, focusing on photovoltaic battery research and manufacturing, and is expanding its market presence [12][41] Group 5 - Luoniushan (000735) is involved in livestock farming and related industries, leveraging Hainan's agricultural resources to expand its market [13][42] - Jingliang Holdings (000505) focuses on oil processing and food manufacturing, utilizing Hainan's logistics advantages for trade [14][43] - Hainan Coconut Island (600238) specializes in alcoholic beverages, particularly health wines, and is expanding its market through tourism channels [15][44] Group 6 - Hainan Haiyao (000566) is a pharmaceutical manufacturer focusing on chemical raw materials and traditional Chinese medicine, benefiting from supportive policies for the pharmaceutical industry [16][45] - Hainan Ruize (002596) produces construction materials and is involved in tourism, aligning its business with Hainan's infrastructure development [17][46] - Hainan Expressway (000886) operates key highways in Hainan and is expanding its business through tourism and duty-free services [18][47] Group 7 - Puli Pharmaceutical (300630) specializes in chemical drug development and international market expansion, leveraging Hainan's trade policies [19][48] - Shennong Technology (300189) focuses on seed research and production, aiming to expand its market through trade policies [20][49] - Shuangcheng Pharmaceutical (002693) is dedicated to peptide drug development and international market expansion, supported by Hainan's policies [21][50] Group 8 - Xinlong Holdings (000955) specializes in non-woven fabrics and related products, with a focus on medical and industrial applications, and is exploring export opportunities [22][51] - ST Intercontinental (600759) is involved in oil and gas exploration and is expanding into the hydrogen energy sector [23][52] - Huawen Group (000793) operates in media, tourism, and supply chain services, aiming for growth through Hainan's logistics advantages [24][53]